Business Wire

New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018

Del

Celgene Corporation (NASDAQ:CELG) today announced the results of two post hoc analyses of data from the phase 3 SUNBEAM™ and RADIANCE™ Part B trials, which evaluated the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1 (S1P1) and 5 (S1P5) receptor modulator, versus a first-line treatment, Avonex® (interferon beta-1a) (IFN), in patients with relapsing multiple sclerosis (RMS). These findings will be presented at ECTRIMS 2018.

“Slowed cognitive processing, which is common in multiple sclerosis, often impairs quality of life for people living with this chronic condition,” said Bruce Cree, M.D., Ph.D., M.A.S., Professor of Neurology at the University of California San Francisco (UCSF) Weill Institute for Neurosciences, Clinical Research Director at the UCSF MS Center and an author of both analyses. “The findings from these new analyses suggest that, when compared to interferon, ozanimod has a beneficial effect on processing speed.”

SUNBEAM evaluated two doses (0.92 mg and 0.46 mg, equivalent to 1 mg and 0.5 mg ozanimod HCI respectively) of oral ozanimod in 1,346 patients with RMS treated for at least one year. A post hoc analysis of 12-month data from SUNBEAM to be presented today examined the effect of ozanimod on cognitive processing speed, based on performance on the Symbol Digit Modalities Test (SDMT). Benefits in SDMT score at month 12 were seen with ozanimod versus IFN (difference: 1.6; 95% confidence interval [CI]: 0.62, 2.56 for ozanimod 1 mg and 1.2; 95% CI: 0.19-2.13 for ozanimod 0.5 mg). More patients exhibited clinically meaningful (≥4-point) improvements in processing speed at month 12 with ozanimod 1 mg (rate ratio, 1.3; 95% CI: 1.05, 1.55) and 0.5 mg (1.2; 95% CI: 0.94, 1.40) versus IFN.

A second post hoc analysis on annualized relapse rates (ARR) and MRI lesions examined the effect of ozanimod in patients with early RMS compared with patients with more advanced disease. Early RMS was defined based on a composite baseline profile, including 3 years or less since diagnosis, an Expanded Disability Status Scale (EDSS) of 3.5 or less, and the use of one or no disease-modifying treatments. In the pooled phase 3 studies, two doses of oral ozanimod (1 mg and 0.5 mg) were evaluated compared with IFN in 2,659 patients treated for two years.

For patients with early RMS (n=1,392) in this analysis, ARR was lower at 12 months with ozanimod 1 mg (ARR=0.149) and ozanimod 0.5 mg (ARR=0.200) compared with IFN (ARR=0.285). ARR was also lower with ozanimod versus IFN in patients with more advanced RMS (n=1,267) (ozanimod 1 mg: 0.217; 0.5 mg: 0.277; IFN: 0.363).

Ozanimod also showed a reduction of MRI lesions in both early and more advanced RMS in this analysis. For patients with early RMS, the mean number of gadolinium-enhancing (GdE) lesions at 12 months was 0.263 with ozanimod 1 mg, 0.458 with ozanimod 0.5 mg and 0.656 with IFN. For those with more advanced RMS, the mean number of GdE lesions was 0.278, 0.323 and 0.915, respectively. Similarly, the mean number of new or enlarging T2 lesions at 12 months for patients with early RMS was 2.952 for ozanimod 1 mg, 3.744 for ozanimod 0.5 mg and 4.633 for IFN. For patients with more advanced RMS, the numbers were 2.514, 2.903 and 4.710, respectively.

“These analyses provide additional encouraging data for ozanimod in relapsing multiple sclerosis, from its potential to influence cognitive processing to showing results in patients with either early or more advanced forms of the disease,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “Ozanimod has the potential to offer the multiple sclerosis community a new oral option for the treatment of relapsing multiple sclerosis, and we continue to work with regulatory bodies in the U.S. and EU in our efforts to bring this treatment to patients.”

In the SUNBEAM and RADIANCE clinical trials, the most common adverse reactions (≥ 5 percent) that were higher with ozanimod than with IFN were upper respiratory tract infections, urinary tract infections, increases of alanine aminotransferase and increases of gamma-glutamyl transferase.

Ozanimod is an investigational compound that is not approved for any use in any country.

About SUNBEAM

SUNBEAM is a pivotal, phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trial evaluating the efficacy, safety and tolerability of two doses of oral ozanimod (0.92 mg and 0.46 mg, equivalent to 1 mg and 0.5 mg ozanimod HCI respectively) against weekly intramuscular interferon beta-1a (Avonex®) over a 12-month treatment period. The study included 1,346 people living with RMS across 152 sites in 20 countries.

The primary endpoint of the trial was ARR during the treatment period. The secondary MRI endpoints included the number of new or enlarging hyperintense T2-weighted brain MRI lesions over 12 months, number of gadolinium-enhanced brain MRI lesions at month 12 and percent change from baseline in brain volume at month 12.

An analysis of the time to onset of 3-month confirmed disability progression was pre-specified using pooled data from both the SUNBEAM and RADIANCE Part B phase 3 trials.

About RADIANCE

RADIANCE Part B is a pivotal, phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trial evaluating the efficacy, safety and tolerability of two doses of oral ozanimod (0.92 mg and 0.46 mg, equivalent to 1 mg and 0.5 mg ozanimod HCI respectively) against weekly intramuscular interferon beta-1a (Avonex®) over a 24-month treatment period. The study included 1,320 people living with RMS across 147 sites in 21 countries.

The primary endpoint of the trial was ARR over 24 months. The secondary MRI endpoints included the number of new or enlarging hyperintense T2-weighted brain MRI lesions over 24 months, number of gadolinium-enhanced brain MRI lesions at month 24 and percent change from baseline in brain volume at month 24.

An analysis of the time to onset of 3-month confirmed disability progression was pre-specified using pooled data from both the SUNBEAM and RADIANCE Part B phase 3 trials.

About Ozanimod

Ozanimod is a novel, oral, selective, sphingosine 1-phosphate 1 (S1P1) and 5 (S1P5) receptor modulator in development for immune-inflammatory indications including relapsing multiple sclerosis, ulcerative colitis and Crohn's disease.

Selective binding with S1P1 is believed to inhibit a specific sub set of activated lymphocytes from migrating to sites of inflammation. The result is a reduction of circulating T and B lymphocytes that leads to anti-inflammatory activity. Importantly, immune surveillance is maintained.

Selective binding with S1P5 is thought to activate specific cells within the central nervous system. This has the potential to enhance remyelination (when the body is able to repair damaged myelin after inflammation is reduced) and prevent synaptic defects. Ultimately, neurological damage may be prevented.

About Multiple Sclerosis

Multiple sclerosis (MS) is a disease in which the immune system attacks the protective myelin sheath that covers the nerves. The myelin damage disrupts communication between the brain and the rest of the body. Ultimately, the nerves themselves may deteriorate — a process that's currently irreversible. Signs and symptoms vary widely, depending on the amount of damage and the nerves affected. Some people living with MS may lose the ability to walk independently, while others experience long periods of remission during which they develop no new symptoms. Multiple sclerosis affects approximately 400,000 people in the U.S. and approximately 2.5 million people worldwide.

Relapsing multiple sclerosis (RMS) is characterized by clearly defined attacks of worsening neurologic function. These attacks — often called relapses, flare-ups or exacerbations — are followed by partial or complete recovery periods (remissions), during which symptoms improve partially or completely with no apparent progression of disease. RMS is the most common disease course at the time of diagnosis. Approximately 85 percent of patients are initially diagnosed with RMS, compared with 10-15 percent with progressive forms of the disease.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next‐generation solutions in protein homeostasis, immuno‐oncology, epigenetics, immunology and neuro‐inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission.

Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.

All trademarks are the property of their respective owners.

###

Contact information

For inquiries, please contact:
Celgene Corporation
Investors:
Nina Goworek
Executive Director, Investor Relations
908-673-9711
or
Media:
Catherine Cantone
Senior Director, Corporate Communications
908-897-4256

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Malta and Austria Are Home to the World’s Best Investment Migration Programs23.10.2018 09:00Pressemelding

The Malta Individual Investor Program is the world’s top citizenship-by-investment program and the Austria Private Residence Program is the world’s top residence-by-investment program, according to the Global Residence and Citizenship Programs 2018–2019 report, released today by global residence and citizenship advisory firm Henley & Partners. Dr. Christian H. Kälin, an international immigration and citizenship law expert and Group Chairman of Henley & Partners, says the annual report provides a systematic analysis and comprehensive benchmarking of the world’s most important programs. “It’s an invaluable tool for anyone interested in alternative residence or citizenship as well as for the professionals like private bankers and lawyers who advise them. It also provides governments with a detailed picture of the broader investment migration industry landscape and where they fit it.” Malta is followed in the citizenship program ranking by Cyprus in 2nd place, Austria in 3rd place, and Ant

Temenos Ramps up AI Efforts to Power its Digital Banking Platform23.10.2018 08:30Pressemelding

Temenos (SIX: TEMN), the banking software company, today announced during the Machine Learning Panel at Sibos that it is increasing the development of Artificial Intelligence capabilities throughout its digital banking platform. The Temenos AI initiative will enable banks to offer personalized services to customers, augment users’ decisions with data-driven machine intelligence, and maximise straight-through-processing (STP) rates for financial transactions at reduced cost with limited or no human intervention. As part of this global initiative, Temenos has just launched a Centre of Excellence for Artificial Intelligence as its innovation engine. The Temenos AI Centre of Excellence will foster a collaborative ecosystem with Temenos’ banking clients and partners to help identify and validate use cases where AI could have an immediate impact on customer experience, as well as operational excellence, and hence improve the bottom line. Temenos’ pioneering initiative will involve injecting

ECAC EDS CB C3 Approval for Smiths Detection Technology23.10.2018 08:00Pressemelding

Smiths Detection has gained ECAC EDS CB C3 approval for the innovative HI-SCAN 6040 CTiX checkpoint scanner. This eliminates the need to remove electronic devices and liquids from hand luggage (subject to local authority guidelines) to make the process more passenger friendly. The HI-SCAN 6040 CTiX delivers the highest levels of security demanded by the new regulations, whilst optimizing checkpoint performance through improved productivity, a better passenger experience and lower operational costs. Removing the need to take out electronic devices and liquids from hand luggage means handling fewer trays which can significantly increase checkpoint throughput and the impressive 0.2m/s belt speed and low false alarm rate also speed up the process. “As the only technology meeting EDS CB C3 (and potentially future C4) standards, Computed Tomography (CT) is undoubtedly the way forward for checkpoint security,” commented Matt Clark, VP Technology & Product Development, Smiths Detection. “With

VIB 9–month profit before tax rises 176% YoY to VND 1,720 billion, Retail revenue increases 92% YoY23.10.2018 07:48Pressemelding

Vietnam International Bank (UPCoM: VIB) announced its financial statements of the first 9 months 2018 with positive results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005507/en/ A clerk at VIB (Photo: Business Wire) Profit before tax grows 176% VIB reported profit before tax of VND 1,720 billion, up 176% year-on-year (YoY), equal to 86% of its full year target. The revenue increased by 48% YoY, in which interest income and non-interest income up 50% and 37% respectively; the latter accounted for 16% of total revenue and continued upward trend. The cost-to-income ratio (CIR) significantly dropped from 57% in 2017 to 48%. Provision expense in 9 months was lower than YoY in the context that VIB no longer has bad debts in VAMC. The return on equity ratio (ROE) reached 19.4%. The total asset of the bank reached over VND 132,500 billion, up 8% year-to-date; lending and deposits reached VND 95,200 billion and VND 89,200

Introducing The Continental Edge: The Easternmost Direct Interconnectivity Point Between Europe and the United States23.10.2018 07:00Pressemelding

Introducing the Continental Edge, the easternmost direct interconnection point between Europe and the United States. Four companies, focused on four key areas of services, have partnered to offer the first holistic solution that delivers best-of-breed colocation, connectivity, internet, and subsea cable solutions. The partnership is an amalgamation of companies brought to market collectivity by 1025Connect (for colocation); Aqua Comms (transatlantic subsea connectivity); DE-CIX (the leading Internet Peering Exchange), and Epsilon (a global network service provider providing on-demand SDN connectivity solutions). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005054/en/ The Continental Edge Map (Graphic: Business Wire) 1025Connect’s data center and colocation facilities serves as the central point where Aqua Comms' AEC-1 cable lands and Epsilon and DE-CIX platforms are available. Any customer connected to Epsilon’s lead

DataCo and SES Networks to Provide Broadband Network for APEC 201823.10.2018 06:50Pressemelding

Ahead of the 26th Asia-Pacific Economic Cooperation (APEC) forum taking place in Papua New Guinea, the PNG Government through its implementing agency, DataCo with the assistance of the Australian Government have chosen SES Networks to provide a managed data service delivering 6Gbps of high-bandwidth, low-latency connectivity to ensure the venues and all delegates have reliable, high-speed internet access during the conference from October to December 2018. SES announced that the service will utilise capacity from its O3b Medium Earth Orbit (MEO) satellite fleet to supplement existing capacity into Papua New Guinea (PNG) and will utilise existing DataCo infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181022006021/en/ DataCo and SES Networks to Provide Broadband Network for APEC 2018 (Photo: Business Wire) To provide additional connectivity to the nation, SES Networks has created a new core network for DataCo, f